Primaxin

   
Google
 
Web NewDrugInformation.com

Primaxin


Drug - Primaxin
The trade name of the product as shown on the labeling.

Dosage - INJECTABLE; INJECTION
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Cilastatin Sodium; Imipenem
Multiple ingredients are in alphabetical order.

Strength - EQ 750MG BASE/VIAL;750MG/VIAL
The potency of the active ingredient(s), Cilastatin Sodium; Imipenem. May repeat for multiple part products.

Applicant - MERCK
The firm name holding legal responsibility for Primaxin. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 050630
The FDA assigned number to Primaxin. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify Primaxin. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Dec 14, 1990
The date Primaxin was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Primaxin. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Primaxin is in. Format is RX, OTC, DISCN.

Applicant Full Name - Merck And Co Inc
The full name of the firm holding legal responsibility for the new application of Primaxin.

Primaxin